Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use YARTEMLEA safely and effectively. See full prescribing information for YARTEMLEA. YARTEMLEA (narsoplimab-wuug) injection, for intravenous use Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
- generic_name
- narsoplimab
- product_names
- narsoplimab
- ndc
- 62225-300, 62225-300-00
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en